Exploring the role of CRISPR in cell-based cancer immunotherapy
The use of CRISPR/Cas9 in cancer immunotherapy
DOI:
https://doi.org/10.47611/jsrhs.v13i1.6029Keywords:
Cancer, Immunotherapy, CRISPR/Cas9, Medicine, CAR-T cellAbstract
Cancer immunotherapy, particularly CAR-T cells, has transformed the landscape of cancer treatment, offering a paradigm shift in prognosis. To enhance the efficacy of cancer treatment, recent scientific endeavors have concentrated on harnessing the potential of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology where they use this technology to cancer treatments and cancer immunotherapy including the engineered CAR-T cell. There have been a lot of advances including correcting genetic mutation, curing genetic disorders, etc. this review paper will cover cancer immunotherapy, CAR-T cell therapy and it;s mechanism, successful clinical trials, ongoing clinical trials, the current limitations as well as the future advantages of this technology.
Downloads
References or Bibliography
“Abecma™ (idecabtagene vicleucel).” n.d. Roswell Park Comprehensive Cancer Center. Accessed August 31,2023. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/abecma.
Afolabi, Lukman O., Mariam O. Afolabi, Musbahu M. Sani, Wahab O. Okunowo, Dehong Yan, Liang Chen, Yaou Zhang, and Xiaochun Wan. 2021. “Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.” (June). https://onlinelibrary.wiley.com/doi/10.1002/cti2.1286.
AYANOĞLU, Fatma B., Ayşe E. ELÇİN, and Yaşar M. ELÇİN. n.d. “Bioethical issues in genome editing by CRISPR-Cas9 technology.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129066/.
But what is CRISPR-Cas9? An animated introduction to Gene Editing. n.d. https://www.youtube.com/watch?v=ANehpGhbuF4.
Chena, Minjiang, Aiwu Mao, Min Xu, Qiaoyou Weng, Jianting Maoa, and Jiansong Ji. n.d. “RISPR-Cas9 for cancer therapy: Opportunities and challenges.” 447 (48-55): 8. https://dpl6hyzg28thp.cloudfront.net/media/CRISPR-Cas9_for_cancer_therapy_Opportunities_and_challenges.pdf.
Ghaffari, Sasan, Nastaran Khalili, and Nima Rezaei. 2021. “CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.” 40, no. 269 (August). https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02076-5#Sec12.
“How CRISPR Is Changing Cancer Research and Treatment.” 2020. National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2020/crispr-cancer-research-treatment.
Immunology: T cell receptor structure and function. n.d. https://www.youtube.com/watch?v=uq9p26JAnCs .
Jogalekar, Manasi P., Ramya L. Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, and Byeong C. Ahn. 2022. “CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.” (Jul). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355792/.
Jogalekar, Manasi P., Ramya L. Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, and Byeong C. Ahn. 2022. “CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.” (Jul). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355792/.
Khalaf, Khalil, Krzysztof Janowicz, Marta Dyszkiewicz-Konwińska, Greg Hutchings, Claudia Dompe, Lisa Moncrieff, Maurycy Jankowski, et al. 2020. “CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.” Genes 11 (8): 921. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463827/.
“Kymriah™ (tisagenlecleucel).” n.d. Roswell Park Comprehensive Cancer Center. Accessed August 31, 2023. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/kymriah.
Lino, Christopher A., Jason C. Harper, James P. Carney, and Jerilyn A. Timlin. 2018. “Delivering CRISPR: a review of the challenges and approaches.” (May). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058482/.
IMalech, Harry L. 2021. “Treatment by CRISPR-Cas9 Gene Editing — A Proof of Principle.” (January). https://www.nejm.org/doi/10.1056/NEJMe2034624?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
NCI. 2022. “CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers.” (March). https://www.cancer.gov/about-cancer/treatment/research/car-t-cells.
NIH. n.d. “PRINCIPLES FOR GOVERNANCE OF HUMAN GENOME EDITING.” ncbi.nlm.nih.gov/books/NBK447266/.
ROBERTS, REBECCA. 2022. “CRISPR in Cancer Therapeutics: CAR-T, NK, TCR and Beyond.” (ARCH). https://www.synthego.com/blog/crispr-cancer-therapy#the-current-landscape-of-crispr-cancer-therapeutics.
“Tecartus™ (brexucabtagene autoleucel).” n.d. Roswell Park Comprehensive Cancer Center. Accessed August 31, 2023. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/tecartus.
Understanding CRISPR-Cas9. n.d. https://www.youtube.com/watch?v=cLMo6DYdJRE.
“U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.” 2022. Johnson & Johnson. https://www.jnj.com/u-s-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-a-bcma-directed-car-t-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma.
Wang, Luyao, Yurong Chen, Xinrui Liu, Ziyi Li, and Xiangpeng Dai. 2022. “The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.” 11, no. 704999 (Jan). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801488/.
Wang, Valentine, Mélanie Gauthier, Véronique Decot, Loïc Reppel, and Danièle Bensoussan. 2023. “Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input.” (Feb). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954171/.
Yadollahpour, Ali. 2021. “CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research.” Frontiers. https://www.frontiersin.org/articles/10.3389/fmed.2021.649896/full.
“Yescarta™ (axicabtagene ciloleucel).” n.d. Roswell Park Comprehensive Cancer Center. Accessed August 31, 2023. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/yescarta.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Meha Farrokhi; Divya B.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
